Passage Bio, INC Form 4 insider transactions

OrbiMed Advisors LLC, a significant shareholder of Passage Bio, Inc., has sold a portion of its common stock holdings in a series of transactions between January 10 and January 14, 2025.

OrbiMed Advisors LLC, a significant shareholder in Passage Bio, Inc., has sold a portion of its holdings over three days in early January 2025.

Lynx1 Capital Management LP reports purchasing 373,645 shares of Passage BIO, Inc. at a weighted average price of $0.6451 per share.

OrbiMed Advisors LLC, a significant shareholder of Passage Bio, Inc., sold 230,321 shares of common stock at a price of $0.60 per share on December 20, 2024.

OrbiMed Advisors LLC has sold a portion of its holdings in Passage Bio, Inc. over three days, reducing its indirect ownership.

OrbiMed Advisors LLC, a significant shareholder in Passage Bio, Inc., has sold a total of 97,103 shares of common stock in two separate transactions.

Lynx1 Capital Management LP, a significant shareholder of Passage Bio, has increased its holdings through a series of open market purchases of common stock.

Edgar B. Cale, GC & Corporate Secretary of Passage Bio, Inc., reports the acquisition of employee stock options.

Director Thomas Richard Kassberg acquired stock options in Passage Bio, Inc. on September 30, 2024.

OrbiMed Advisors LLC, a significant shareholder of Passage Bio, Inc., disposed of 39,300 shares of common stock at an average price of $0.71 per share on September 19, 2024.

OrbiMed Advisors LLC, a significant shareholder of Passage Bio, Inc., has sold a portion of its holdings in a series of transactions between September 16 and September 18, 2024.

Athena Countouriotis, a director at Passage Bio, Inc., was granted stock options to purchase 47,693 shares of common stock on May 21, 2024.

Maxine Gowen, a director at Passage Bio, Inc., was granted stock options to purchase 47,693 shares of common stock on May 21, 2024.

Sandip Kapadia, a director at Passage Bio, Inc., was granted stock options to purchase 47,693 shares of common stock at an exercise price of $1.28 on May 21, 2024.

Director Saqib Islam of Passage Bio, Inc. (PASG) was granted stock options on May 21, 2024.

Director Sondhi Dolan acquired stock options in Passage Bio, Inc. on May 21, 2024.

Director Derrell Porter acquired 47,693 stock options in Passage Bio, Inc. on May 21, 2024.

Kathleen Borthwick, CFO of Passage Bio, Inc., reports the acquisition of 227,000 employee stock options on March 15, 2024.

Chief Medical Officer Mark S. Forman receives stock options for 203,000 shares of Passage Bio, Inc. common stock.

William Chou, President and CEO of Passage Bio, Inc., acquired 575,000 employee stock options on March 15, 2024.

Edgar B. Cale, GC & Corporate Secretary of Passage Bio, Inc., reports the acquisition of 203,000 employee stock options on March 15, 2024.